Generics Bulletin
Pfizer Eyes EU Pegfilgrastim Roll-Out By 1 April As US Launch Is Confirmed
By Dean Rudge 25 Jan 2021
Pfizer will aim to have its biosimilar Neulasta (pegfilgrastim) product, Nyvepria, on the market in both the EU and US...
The US Biosimilars Perspectives article pack – your key to critical insights.
Your free pack includes the articles:
Generics Bulletin
By Dean Rudge 25 Jan 2021
Pfizer will aim to have its biosimilar Neulasta (pegfilgrastim) product, Nyvepria, on the market in both the EU and US...
Generics Bulletin
By Dean Rudge 25 Jan 2021
With a biosimilar Lucentis (ranibizumab) candidate recently filed and Soliris (eculizumab), Eylea (aflibercept) and Prolia (denosumab) candidates in Phase III...
Generics Bulletin
By David Wallace 25 Jan 2021
Attendees to Medicines for Europe’s Regulatory Affairs and Pharmacovigilance virtual conference heard that a window of opportunity to optimize the...
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: